Αποτελέσματα Αναζήτησης
21 Αυγ 2009 · According to data from the Sequential Tarceva in Unresectable NSCLC (SATURN) trial, which was presented at the 13th World Conference on Lung Cancer, maintenance therapy with erlotinib improved overall survival in patients with advanced NSCLC after initially successful chemotherapy.
Tarceva® (erlotinib) is a first-generation, selective, reversible inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase (TKI) binding with high affinity to the common EGFR mutations occurring in non-small cell lung cancer (NSCLC), notably exon 19 deletions or exon 21 (L858R) substitution. 1.
May 20, 2010 — Results from the phase 3 Sequential Tarceva in Unresectable NSCLC (SATURN) trial are now published online in The Lancet Oncology.
13 Ιουλ 2009 · Roche announced today that SATURN, a pivotal Phase III study, met a key secondary endpoint of extending overall survival in patients with advanced non-small cell lung cancer (NSCLC) who received...
24 Αυγ 2009 · SAN FRANCISCO–Maintenance therapy with erlotinib (Tarceva) in patients with non-small-cell lung cancer following chemotherapy provided a statistically significant improvement in survival, according to results from the SATURN trial.
This page shows Saturn location and other relevant astronomical data in real time. The celestial coordinates, magnitude, distances and speed are updated in real time and are computed using high quality data sets provided by the JPL Horizons ephemeris service (see acknowledgements for details).
2 Αυγ 2009 · August 1, 2009 (San Francisco, California) — New results from the phase 3 SATURN trial show that erlotinib (Tarceva) maintenance therapy significantly improves overall survival in...
